Summary unavailable.

Questions

Question 1

What is the primary purpose of using lipid-lowering agents as part of a total plan?

View answer and explanation
Question 2

How do HMG-CoA reductase inhibitors, such as atorvastatin and simvastatin, work to lower blood lipids?

View answer and explanation
Question 3

Which of the following drugs is an example of a bile acid sequestrant?

View answer and explanation
Question 4

What is the primary site of action where Ezetimibe inhibits cholesterol absorption?

View answer and explanation
Question 5

According to the 'Contraindications' section, in which patient population are HMG-CoA reductase inhibitors specifically contraindicated?

View answer and explanation
Question 6

What is the recommended trial period for dietary therapy before initiating drug therapy with lipid-lowering agents?

View answer and explanation
Question 7

Which group of vitamins may be bound by bile acid sequestrants like cholestyramine and colestipol?

View answer and explanation
Question 8

Concurrent use of which of the following drugs with an HMG-CoA reductase inhibitor increases the risk of myopathy?

View answer and explanation
Question 9

What is the recommended course of action if a patient taking a lipid-lowering medication experiences a paradoxical increase in their cholesterol level?

View answer and explanation
Question 10

For how long is lipid-lowering therapy typically continued if no clinical response is evident?

View answer and explanation
Question 11

Which lab tests should be evaluated before initiating and periodically throughout therapy with lipid-lowering agents?

View answer and explanation
Question 12

What lifestyle modifications should be used in conjunction with lipid-lowering medications, according to patient teaching guidelines?

View answer and explanation
Question 13

Which class of lipid-lowering agents works by binding cholesterol in the GI tract?

View answer and explanation
Question 14

In addition to evaluating cholesterol and triglycerides, what other function tests should be assessed before and periodically throughout lipid-lowering therapy?

View answer and explanation
Question 15

Which of the following drugs is NOT listed as an HMG-CoA reductase inhibitor?

View answer and explanation
Question 16

Combining an HMG-CoA reductase inhibitor with cyclosporine can increase the risk of what adverse effect?

View answer and explanation
Question 17

What is one of the desired outcomes of lipid-lowering therapy regarding cholesterol ratios?

View answer and explanation
Question 18

What key historical information should be obtained from a patient before starting lipid-lowering therapy?

View answer and explanation
Question 19

What is the mechanism of action for fenofibrate and gemfibrozil?

View answer and explanation
Question 20

Which of the following drugs is NOT listed as increasing the risk of myopathy when used with HMG-CoA reductase inhibitors?

View answer and explanation
Question 21

What is the desired outcome regarding serum triglyceride levels from lipid-lowering therapy?

View answer and explanation
Question 22

What general contraindication is mentioned for lipid-lowering agents in the text?

View answer and explanation
Question 23

According to the implementation guidelines, what should be done to determine the timing of doses in relation to meals?

View answer and explanation
Question 24

The text states that HMG-CoA reductase inhibitors, such as fluvastatin and pitavastatin, inhibit what?

View answer and explanation
Question 25

Besides fat and cholesterol, what other dietary components should be restricted as part of patient teaching for lipid-lowering therapy?

View answer and explanation
Question 26

What is the primary action of bile acid sequestrants like colestipol and colesevelam?

View answer and explanation
Question 27

What is a potential interaction when bile acid sequestrants are taken with other concurrently administered drugs?

View answer and explanation
Question 28

What is the desired outcome regarding LDL cholesterol levels from lipid-lowering therapy?

View answer and explanation
Question 29

According to the 'Precautions' section, what is a key step that should be taken before drug therapy for high lipids is initiated?

View answer and explanation
Question 30

In addition to diet and exercise, what other lifestyle change is recommended in the patient teaching section for individuals on lipid-lowering agents?

View answer and explanation
Question 31

Fenofibrate, gemfibrozil, and niacin are lipid-lowering agents that act by which of the following mechanisms?

View answer and explanation
Question 32

The safety of lipid-lowering drugs has not been established in which specific populations, according to the 'Precautions' section?

View answer and explanation
Question 33

What is the consequence of combining HMG-CoA reductase inhibitors with drugs like niacin, erythromycin, gemfibrozil, or cyclosporine?

View answer and explanation
Question 34

The therapeutic goal of lowering blood lipids with agents like statins is to reduce the morbidity and mortality associated with what condition?

View answer and explanation
Question 35

Which of the following is NOT a lipid-soluble vitamin mentioned as being at risk of binding by bile acid sequestrants?

View answer and explanation
Question 36

When should liver function tests be assessed for a patient on lipid-lowering therapy?

View answer and explanation
Question 37

How does cholestyramine, a bile acid sequestrant, lower lipid levels?

View answer and explanation
Question 38

What is the consequence of HMG-CoA reductase inhibitors being contraindicated in pregnancy?

View answer and explanation
Question 39

What is a key difference in the mechanism of action between HMG-CoA reductase inhibitors and ezetimibe?

View answer and explanation
Question 40

Which of the following drugs is NOT a bile acid sequestrant?

View answer and explanation
Question 41

What is the recommended dietary trial period in months before initiating drug therapy with lipid-lowering agents?

View answer and explanation
Question 42

After how many months of lipid-lowering therapy with no evident clinical response should the therapy typically be discontinued?

View answer and explanation
Question 43

The patient teaching guidelines advise that lipid-lowering medications should be used in conjunction with what?

View answer and explanation
Question 44

The primary goal of therapy with lipid-lowering agents is the prevention of end-organ damage from what underlying disease process?

View answer and explanation
Question 45

Which of the following is an example of an HMG-CoA reductase inhibitor?

View answer and explanation
Question 46

The interaction between bile acid sequestrants and vitamins primarily affects which type of vitamins?

View answer and explanation
Question 47

What is the clinical significance of monitoring liver function tests in patients taking lipid-lowering agents?

View answer and explanation
Question 48

What are the three main classes of lipid-lowering agents described in the 'General Action and Information' section?

View answer and explanation
Question 49

What is the recommended patient action if a paradoxical increase in cholesterol level occurs while on lipid-lowering therapy?

View answer and explanation
Question 50

What potential interaction exists between bile acid sequestrants and the four vitamins A, D, E, and K?

View answer and explanation

Other chapters

HOW TO USE DAVIS'S DRUG GUIDE FOR NURSESEVIDENCE-BASED PRACTICE AND PHARMACOTHERAPEUTICS: Implications for NursesPHARMACOGENOMICSMEDICATION ERRORS: Improving Practices and Patient SafetyDETECTING AND MANAGING ADVERSE DRUG REACTIONSOVERVIEW OF RISK EVALUATION AND MITIGATION SYSTEMS (REMS)SPECIAL DOSING CONSIDERATIONSTHE CYTOCHROME P450 SYSTEMEDUCATING PATIENTS ABOUT SAFE MEDICATION USEAnti-Alzheimer's agentsAntianemicsAntianginalsAntianxiety agentsAntiarrhythmicsAntiasthmaticsAnticholinergicsAnticoagulantsAnticonvulsantsAntidepressantsAntidiabeticsAntidiarrhealsAntiemeticsAntifungalsAntihistaminesAntihypertensivesAnti-infectivesAntineoplasticsAntiparkinson agentsAntiplatelet agentsAntipsychoticsAntipyreticsAntirheumaticsAntiulcer agentsAntiviralsBeta blockersBone resorption inhibitorsBronchodilatorsCalcium channel blockersCentral nervous system stimulantsCorticosteroidsDiureticsHormonesImmunosuppressantsLaxativesMinerals/electrolytes/pH modifiersNonopioid analgesicsNonsteroidal anti-inflammatory agentsOpioid analgesicsSedative/hypnoticsSkeletal muscle relaxantsThrombolyticsVaccines/immunizing agentsVitaminsDRUGS APPROVED IN CANADANATURAL/HERBAL PRODUCTSMEDICATION SAFETY TOOLSAppendix A. Recent Drug ApprovalsAppendix E. Administering Medications to ChildrenAppendix G. Pediatric Dosage CalculationsAppendix I. Controlled Substance SchedulesAppendix L. Insulins and Insulin TherapyAppendix M. Canadian and U.S. Pharmaceutical PracticesAppendix N. Routine Pediatric and Adult Immunizations